Human menstrual blood-derived stem cells as immunoregulatory therapy in COVID-19: A case report and review of the literature

BACKGROUND The coronavirus disease 2019 (COVID-19) caused by novel coronavirus 2019 in December 2019 has spread all around the globe and has caused a pandemic. There is still no current effective guidance on the clinical management of COVID-19. Mesenchymal stem cell therapy has been shown to be one of the therapeutic approaches to alleviate pneumonia and symptoms through their immunomo-dulatory effect in COVID-19 patients. CASE SUMMARY We describe the first confirmed case of COVID-19 in Hangzhou to explore the role of human menstrual blood-derived stem cells (MenSCs) in the treatment of COVID-19. Moreover, we review the immunomodulation effect including non-specific and specific immune functions of MenSCs for the therapy of COVID-19. CONCLUSION MenSCs can be helpful to find a promising therapeutic approach for COVID-19.

[1]  R. Perlingeiro,et al.  SSEA-4 identifies mesenchymal stem cells from bone marrow. , 2007, Blood.

[2]  C. Xiang,et al.  The multi-functional roles of menstrual blood-derived stem cells in regenerative medicine , 2019, Stem Cell Research & Therapy.

[3]  S. Kadam,et al.  Mesenchymal stem cells and exosome therapy for COVID-19: current status and future perspective , 2020, Human Cell.

[4]  C. Chakraborty,et al.  SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options. , 2020, European review for medical and pharmacological sciences.

[5]  Ashish Ranjan Sharma,et al.  Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know More , 2020, Archives of Medical Research.

[6]  F. Djouad,et al.  The immunosuppressive signature of menstrual blood mesenchymal stem cells entails opposite effects on experimental arthritis and graft versus host diseases , 2016, Stem cells.

[7]  C. Chakraborty,et al.  Development of epitope‐based peptide vaccine against novel coronavirus 2019 (SARS‐COV‐2): Immunoinformatics approach , 2020, Journal of medical virology.

[8]  C. Xiang,et al.  Transplantation of Menstrual Blood-Derived Mesenchymal Stem Cells Promotes the Repair of LPS-Induced Acute Lung Injury , 2017, International journal of molecular sciences.

[9]  L. Cancio,et al.  The promise of mesenchymal stem cell therapy for acute respiratory distress syndrome , 2018, The journal of trauma and acute care surgery.

[10]  P. Sanberg,et al.  Recent progress in cell therapy for basal ganglia disorders with emphasis on menstrual blood transplantation in stroke , 2012, Neuroscience & Biobehavioral Reviews.

[11]  S. Lo,et al.  A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster , 2020, The Lancet.

[12]  J. Laffey,et al.  Recent insights: mesenchymal stromal/stem cell therapy for acute respiratory distress syndrome , 2016, F1000Research.

[13]  K. Webster,et al.  Human endometrial stem cells confer enhanced myocardial salvage and regeneration by paracrine mechanisms , 2013, Journal of cellular and molecular medicine.

[14]  J. Cuenca,et al.  Characterization of menstrual stem cells: angiogenic effect, migration and hematopoietic stem cell support in comparison with bone marrow mesenchymal stem cells , 2015, Stem Cell Research & Therapy.

[15]  B. Thompson,et al.  Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. , 2015, The Lancet. Respiratory medicine.

[16]  Shan Liu,et al.  Mesenchymal stem cells as a potential therapy for COVID-19 , 2020, Stem Cell Research & Therapy.

[17]  Angham G. Hadi,et al.  A Review on COVID-19: Origin, Spread, Symptoms, Treatment, and Prevention , 2020 .

[18]  C. Xiang,et al.  Exosomes derived from human menstrual blood-derived stem cells alleviate fulminant hepatic failure , 2017, Stem Cell Research & Therapy.

[19]  Moustapha Hassan,et al.  Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells , 2004, The Lancet.

[20]  B. Badran,et al.  The immunomodulatory properties of human bone marrow-derived mesenchymal stromal cells are defined according to multiple immunobiological criteria , 2016, Inflammation Research.

[21]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[22]  Victor M Corman,et al.  Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[23]  Q. Pham,et al.  Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam , 2020, The New England journal of medicine.

[24]  Xiaobing Gong,et al.  Clinical features of familial clustering in patients infected with 2019 novel coronavirus in Wuhan, China , 2020, Virus Research.

[25]  R. Jacobs,et al.  Human Umbilical Cord-Derived Mesenchymal Stem Cells Utilize Activin-A to Suppress Interferon-γ Production by Natural Killer Cells , 2014, Front. Immunol..

[26]  C. Xiang,et al.  Menstrual blood-derived stem cells: toward therapeutic mechanisms, novel strategies, and future perspectives in the treatment of diseases , 2019, Stem Cell Research & Therapy.

[27]  Hongzhou Lu,et al.  Drug treatment options for the 2019-new coronavirus (2019-nCoV). , 2020, Bioscience trends.

[28]  A. Khojasteh,et al.  The Clinical Trials of Mesenchymal Stem Cell Therapy in Skin Diseases: An Update and Concise Review. , 2019, Current stem cell research & therapy.

[29]  S. Lindstrom,et al.  First Case of 2019 Novel Coronavirus in the United States , 2020, The New England journal of medicine.

[30]  Lanjuan Li,et al.  Immunomodulatory effect of mesenchymal stem cells in chemical-induced liver injury: a high-dimensional analysis , 2019, Stem Cell Research & Therapy.

[31]  Hanxiong Guan,et al.  Imaging changes in patients with 2019-nCov , 2020, European Radiology.

[32]  Hedayat Sahraei,et al.  The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of “inflame-aging” , 2020, Inflammation Research.

[33]  C. Xiang,et al.  Transplantation of human menstrual blood progenitor cells improves hyperglycemia by promoting endogenous progenitor differentiation in type 1 diabetic mice. , 2014, Stem cells and development.

[34]  Haibo Xu,et al.  Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer , 2020, Journal of Thoracic Oncology.

[35]  Yuelin Zhang,et al.  Mechanisms underlying the protective effects of mesenchymal stem cell-based therapy , 2020, Cellular and Molecular Life Sciences.

[36]  J. Sznajder,et al.  Macrophage-epithelial paracrine crosstalk inhibits lung edema clearance during influenza infection. , 2016, The Journal of clinical investigation.

[37]  Xiaolong Qi,et al.  CT Imaging of the 2019 Novel Coronavirus (2019-nCoV) Pneumonia , 2020, Radiology.

[38]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[39]  Sheng Ding,et al.  Long-term self-renewal and directed differentiation of human embryonic stem cells in chemically defined conditions. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[40]  W. Seeger,et al.  Mesenchymal Stem Cells in Fibrotic Disease. , 2017, Cell stem cell.

[41]  A. Uccelli,et al.  The immunomodulatory function of mesenchymal stem cells: mode of action and pathways , 2015, Annals of the New York Academy of Sciences.

[42]  M. Shokri,et al.  Menstrual Blood-Derived Stromal Stem Cells Augment CD4+ T Cells Proliferation , 2018, Avicenna journal of medical biotechnology.

[43]  Tianyuan Wang,et al.  Cytokine storm intervention in the early stages of COVID-19 pneumonia , 2020, Cytokine & Growth Factor Reviews.

[44]  Lanjuan Li,et al.  Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19 , 2020, Frontiers of Medicine.

[45]  I. Nikokar,et al.  Efficient generation of functional hepatocyte‐like cells from menstrual blood‐derived stem cells , 2015, Journal of tissue engineering and regenerative medicine.

[46]  Ashish Ranjan Sharma,et al.  Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19 , 2020, Frontiers in Pharmacology.

[47]  Ashish Ranjan Sharma,et al.  The 2019 novel coronavirus disease (COVID-19) pandemic: A zoonotic prospective , 2020 .

[48]  M. Exline,et al.  Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. , 2019, The Lancet. Respiratory medicine.

[49]  F. Figueroa,et al.  The Promising Potential of Menstrual Stem Cells for Antenatal Diagnosis and Cell Therapy , 2014, Front. Immunol..

[50]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[51]  F. Ezquer,et al.  The Reparative Abilities of Menstrual Stem Cells Modulate the Wound Matrix Signals and Improve Cutaneous Regeneration , 2018, Front. Physiol..